Registration
To register on the website, please contact the site administrator at cardio2share@semmelweis-univ.hu with your full name, who will send you the login details.
Attention! By registering, you accept the privacy policy applicable to the operation of this website. For details, see the link Privacy policy.
CA17129 – Catalysing transcriptomics research in cardiovascular disease
CardioRNA COST Action CA17129 (Start of the Action: 03/10/2018, End of Action: 02/10/2022) was a collaborative pan-European network that brought together multidisciplinary researchers, clinicians, and industrial partners with the goal of accelerating the understanding of transcriptomics in cardiovascular disease (CVD) and advancing the translation of experimental findings into clinical applications for personalized medicine.
CVD remains the leading global cause of death, and despite ongoing advancements, there continues to be a critical need for improved diagnostic tools, prognostic markers, and therapies. The human transcriptome, which encompasses all RNA molecules produced in a cell, is far more complex than previously understood. However, the lack of communication between researchers and industry partners, along with the absence of standardized guidelines for data generation, made it difficult to compare and replicate results effectively.
CardioRNA successfully addressed these challenges by fostering collaboration between stakeholders with diverse expertise, which facilitated the rapid deciphering of RNA functions and interactions within the context of cardiovascular disease. Additionally, CardioRNA refined guidelines for transcriptomics investigations in CVD to increase the reproducibility of results, thus facilitating the development of clinical products. The Action also disseminated knowledge and supported capacity-building through various meetings, prioritizing students and early career investigators. As a result, CardioRNA advanced studies on cardiovascular transcriptomics, generated innovative projects, and consolidated the leadership of European research groups in the field.
CA21153 - AtheroNET – Network for implementing multiomic approaches in atherosclerotic cardiovascular disease prevention and research AtheroNET COST Action CA21153 (Start Date: 19 October 2022, End Date: 19 October 2026), which includes many members of the CardioRNA COST Action, aims to consolidate and connect experts from different fields into a European and international network focused on using multiple omics technologies and data integration through machine learning/artificial intelligence (ML/AI) approaches to bring novel paradigms in the prevention, diagnosis, and treatment of atherosclerotic cardiovascular disease (ASCVD).
Current CVD-related initiatives and networks are often centered on specific aspects of CVD and/or specific methodologies. AtheroNET offers a comprehensive environment in which different stakeholders—including basic scientists, clinicians, bioinformaticians, industry representatives, and patient representatives—will address current challenges by:
- Organizing multi-centric studies for cross-validation of different genomic, transcriptomic, proteomic, and metabolomic traits related to atherosclerosis;
- Fostering collaborative research efforts through European funds to investigate novel pathophysiological mechanisms and identify prognostic, diagnostic, and therapeutic ASCVD targets;
- Promoting inter-sectorial cooperation with the private sector to commercialize novel scientific achievements and secure their delivery to the market;
- Organizing inter-laboratory dialogs and ring trials to standardize and harmonize different wet-lab and dry-lab workflows;
- Utilizing specific ML/AI algorithms for data integration and the design of innovative multi-omic models.